Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, has announced publication of clinical dosimetry data for Radspherin in the Journal of Nuclear Medicine, one of the leading peer-reviewed journals in the field.
The publication, titled ‘Normal Tissue Dosimetry of Intraperitoneal Radium-224-Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases’, reports results from nine patients enrolled in the dosimetry cohorts of the Phase 1 Radspherin studies in ovarian and colorectal cancer. Positive final data from these studies, previously reported by Oncoinvent, demonstrated a favourable safety profile and encouraging efficacy signals.
The dosimetry study, conducted at The Norwegian Radium Hospital, part of Oslo University Hospital, evaluated how radiation from Radspherin is distributed to normal tissues following treatment. Results showed that absorbed radiation doses to normal organs were below levels commonly associated with risks for complications, including for organs typically regarded as activity-limiting such as the kidneys and red bone marrow.
